• Explore /
  • Poster
  • / The Chinese subgroup from a randomized phase III study of lapatinib in combination with weekly paclitaxel versus weekly paclitaxel alone as second-line treatment of HER2-amplified advanced gastric cancer (AGC) in Asian countries.

The Chinese subgroup from a randomized phase III study of lapatinib in combination with weekly paclitaxel versus weekly paclitaxel alone as second-line treatment of HER2-amplified advanced gastric cancer (AGC) in Asian countries.

Abstract Poster

Authors

null

Guo-ping Sun

Department of Oncology, The First Affiliated Hospital of An Hui Medical University, Hefei, China

Guo-ping Sun , Yan Sun , Rui-hua Xu , Jian-Ming Xu , Jin Li , Jin-Wan Wang , Shukui Qin , Ji Feng Feng , Yi Ba , Lin Shen , Yu-Xian Bai , Yihong Sun , Hongming Pan , Ying Cheng , Shiying Yu , Haijun Zhong , Li Bai , Rongcheng Luo , Mikiro Kobayashi , Atsushi Ohtsu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer

Clinical Trial Registration Number

NCT00486954

Citation

J Clin Oncol 31, 2013 (suppl; abstr 4109)

DOI

10.1200/jco.2013.31.15_suppl.4109

Abstract #

4109

Poster Bd #

24G

Abstract Disclosures

Similar Posters

First Author: Yung-Jue Bang

First Author: Timothy Jay Price

First Author: Yee Chao

First Author: Markus H. Moehler